SynthesisBMC gastroenterology2025
Ulinastatin for the treatment of severe acute pancreatitis: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Serum CCL1 discriminates infectious and sterile systemic inflammation in sepsis and acute pancreatitis.Scientific reports · 2026Article
- Non-invasive liquid biopsy based on metabolomic profiling improves diagnosis and early warning of severe acute pancreatitis.NPJ digital medicine · 2026Article
- Effects of meropenem plus ulinastatin on inflammatory response and complications in patients with severe septic shock.Frontiers in medicine · 2026Article
- Ulinastatin-somatostatin combination for acute severe pancreatitis: enhanced clinical efficacy and reduced serum inflammation.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute pancreatitis (SAP) lacks a definitive treatment option. Although ulinastatin has demonstrated anti-inflammatory and organ-preserving properties, its role in SAP remains unclear due to divergent findings. Hence, we evaluated the efficacy and role of ulinastatin in patients with SAP.
methodsA systematic review and meta-analysis were performed according to the 2020 PRISMA guidelines. An extensive search was performed in databases including PubMed, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Embase, IndMED, Cochrane Library, Cochrane Methodology Register, and Cochrane Database of Systematic Reviews to obtain relevant data. Prospective and retrospective studies evaluating patients aged ≥ 18 years with SAP were included. Factors including mortality rate, hospitalisation duration, acute physiology and chronic health evaluation (APACHE-II) score, white blood cell (WBC) count, c-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and time to abdominal pain disappearance were assessed.
resultsThe pooled analysis of seven studies revealed a significant reduction in mortality risk, [risk ratio, (95% CI: 0.20, 0.65); i
conclusionUlinastatin, administered either alone or in combination with other therapeutic agents, was associated with significant improvements in clinical outcomes and reduced mortality rates in patients with severe acute pancreatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.